Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| 38.65 | |
| 38.71 | |
| - | |
| 39.5 | |
| 38.25 | |
| 25.57-75.017 | |
| 2 205 M | |
| 57 048 K | |
| 0 | |
| -0.57 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Structure Therapeutics GPCR, a clinical-stage company, is expected to report second-quarter 2024 results soon. Structure Therapeutics’ lead product candidate is GSBR-1290, a highly selective oral G...
With Eli Lilly up by a stunning 47% so far this year, many investors are likely prone to feeling they're stuck on the sidelines after this bull run. Even if there's plenty of upside left -- and in Eli...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
